Dual Inhibitors as a New Challenge for Cancer Multidrug Resistance Treatment

Discovery of Potent Inhibitors for Breast Cancer Multidrug Resistance

W4: Cancer Stem Cells as a New Target Point for Treatment of Glioblastoma

Glioblastoma is a destructive form of brain tumor that kills most patients within two years of diagnosis.Treatments for glioblastoma include the usual options of surgery, radiation therapy and chemotherapy, but there is no effective treatment. The tumors are capable of spreading tendrils out into the brain and it can grow back in a matter of months after being removed. The cancer stem cell...

A review on miRNAs as new biomarkers for colorectal cancer

Background & Objective: Since colorectal cancer does not often have phenotypic symptoms in the early stages, the study of biomarkers for the diagnosis and prognosis of the tumor is very important. MicroRNAs are one of the most important biomarkers which attract the attention of many researchers due to a variety of reasons, including their non-invasive nature; these molecules are a group of non-...

Coronavirus as a New Challenge for Infection Control in Dentistry: A Literature Review

 Modes of transmission of the COVID-19 virus are still unclear. The virus could spread through direct routes, including aerosols and saliva, and indirect transmission through contaminated surfaces. Dental practitioners produce airborne infectious particles especially when using rotary instruments during treatment. Oral fluids, blood, and oral mucosa are also sources of infection, so dentists ar...

Molecular mechanisms involved in multidrug resistance in breast cancer therapy

Breast cancer is the most prevalent cancer in women. Chemotherapy is the main strategy in the treatment of this disease especially in the advanced form of the disease. Despite the recent progress in the development of new chemotherapy, the effectiveness of these drugs has dramatically reduced due to multidrug resistance. The phenotype of multidrug resistance (MDR) can occur through different me...